03:38 PM EST - Paladin Labs Inc. : announced today that it has filed a new drug submission for Oralair(TM) with Health Canada. Oralair(TM) is a sublingual grass pollen immunotherapy tablet for the treatment of grass pollen rhinitis with or without conjunctivitis for patients uncontrolled with current symptomatic medications. Paladin Labs Inc.
shares T.PLB are trading up $0.76 at $44.46.
